Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 8/20 | 0.48 |
| ▸ | MME | P08473 | 2/20 | 0.45 |
| ▸ | ACE | P12821 | 2/20 | 0.45 |
| ▸ | CASP3 | P42574 | 2/20 | 0.41 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.41 |
| ▸ | LCK | P06239 | 9/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | IL1B | P01584 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1409934 | 1.00 | CASP1 (0.48) | CASP1MMEACECASP3CASP8 | |
| SCHEMBL12994873 | 0.89 | CASP1 (0.51) | CASP1MMEACECASP3CASP8 | |
| SCHEMBL645962 | 0.88 | ACE (0.57) | CASP1MMEACELCKTDP1 | |
| SCHEMBL645612 | 0.88 | ACE (0.57) | CASP1MMEACELCKTDP1 | |
| SCHEMBL13139910 | 0.88 | ACE (0.57) | CASP1MMEACELCKTDP1 | |
| SCHEMBL1409780 | 0.85 | CASP1 (0.64) | CASP1MMEACECASP3CASP8 | |
| SCHEMBL3069962 | 0.85 | CASP1 (0.64) | CASP1MMEACECASP3CASP8 | |
| SCHEMBL12098331 | 0.81 | MME (0.44) | CASP1MMEACECASP3CASP8 | |
| SCHEMBL12098327 | 0.81 | MME (0.44) | CASP1MMEACECASP3CASP8 | |
| SCHEMBL2219237 | 0.80 | CASP1 (0.59) | CASP1MMEACECASP3CASP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178069-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178069-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1A, IFNAR1, IL1B | CASP1 6/4885MME 279/4885ACE 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.